Tvardi Therapeutics (NASDAQ:TVRD) Given Buy Rating at BTIG Research

BTIG Research restated their buy rating on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock.

TVRD has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen raised Tvardi Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.50.

Tvardi Therapeutics Price Performance

NASDAQ TVRD opened at $3.00 on Wednesday. The company has a market capitalization of $28.14 million, a PE ratio of -0.54 and a beta of 0.14. The company has a fifty day moving average of $3.78 and a 200 day moving average of $8.96. Tvardi Therapeutics has a 1 year low of $2.81 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.23).

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TVRD. Arax Advisory Partners grew its position in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after acquiring an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the 2nd quarter worth about $43,000. HRT Financial LP purchased a new position in Tvardi Therapeutics during the fourth quarter worth approximately $47,000. Finally, XTX Topco Ltd purchased a new position in Tvardi Therapeutics during the fourth quarter worth approximately $55,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.